Opioid Quota Reform Act

Summary

Opioid Quota Reform Act This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

5 official files

• Reported to Senate (text)

  Reported to Senate · EN · 19 June 2018

  ViewDownloadOpen at official source

• Reported to Senate (PDF)

  Reported to Senate · EN · 19 June 2018

  ViewDownloadOpen at official source

• Introduced in Senate (text)

  Introduced in Senate · EN · 12 March 2018

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 12 March 2018

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 12 March 2018

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.